Epidermal growth factor receptor‐targeted treatment for advanced colorectal carcinoma

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

Cancer Statistics, 2004

2004 • 4,026 citations

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

Epidermal growth factor-related peptides and their receptors in human malignancies

1995 • 2,689 citations

Growth Factors and Cancer

1991 • 2,044 citations

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

2004 • 1,709 citations

Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor

2002 • 1,308 citations

Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains

2002 • 1,158 citations

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

2001 • 995 citations

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

2000 • 934 citations

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

1997 • 841 citations

The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy

1999 • 840 citations

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

1997 • 828 citations

Improving the efficacy of antibody-based cancer therapies

2001 • 821 citations

EGF receptor

1999 • 792 citations

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

2000 • 766 citations

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

1999 • 707 citations

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

2001 • 642 citations

Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.

2000 • 549 citations

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

2001 • 452 citations

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, andmdr gene expression in colorectal cancer

1993 • 415 citations

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

2000 • 376 citations

Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis.

2002 • 374 citations

Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma

2001 • 360 citations

Cancer Management: A Multidisciplinary Approach

2007 • 342 citations

Monoclonal antibodies as therapeutic agents for cancer

2004 • 320 citations

Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells.

1995 • 317 citations

Signaling through the epidermal growth factor receptor during the development of malignancy

2004 • 305 citations

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

2003 • 282 citations

Human Antibody Effector Function

1992 • 266 citations

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

2003 • 264 citations

Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.

1993 • 245 citations

EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma

1998 • 243 citations

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

2001 • 232 citations

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

2004 • 218 citations

Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab

2004 • 208 citations

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

2003 • 178 citations

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

2006 • 175 citations

Clinical experience with CD64-directed immunotherapy. An overview

1997 • 146 citations

Nuclear targeting of Bax during apoptosis in human colorectal cancer cells

1998 • 138 citations

Metastatic colorectal cancer

2001 • 130 citations

Inhibition of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases as an Approach to Cancer Chemotherapy

1999 • 128 citations

Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.

2000 • 126 citations

Epidermal Growth Factor Receptor as a Therapeutic Target in Colorectal Cancer

2003 • 121 citations

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer

2001 • 119 citations

Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer

2003 • 110 citations

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

1996 • 103 citations

Growth factor signaling in cell survival: implications for cancer treatment.

2001 • 90 citations

A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer

2004 • 88 citations

ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis

2004 • 86 citations

Monoclonal antibodies as therapeutics in oncology

2002 • 84 citations

Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774)

2004 • 84 citations

Clinical Implications of the EGF Receptor/Ligand System for Tumor Progression and Survival in Gastrointestinal Carcinomas: Evidence for New Therapeutic Options

2003 • 68 citations

Structure, function and transforming potential of the epidermal growth factor receptor

1990 • 64 citations

Uncommon Presentations of Hodgkin's Disease

2003 • 60 citations

A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.

2003 • 57 citations

Tyrosine Kinase Inhibitors. 13. Structure−Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor

1997 • 57 citations

Epidermal growth factor receptor expression and measurement in solid tumors

2002 • 55 citations

Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in Gastric and Colorectal Carcinomas1

1993 • 53 citations

Therapeutics targeting signal transduction for patients with colorectal carcinoma

2002 • 53 citations

Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?

2004 • 50 citations

Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial

2005 • 49 citations

Epidermal growth factor receptor expression and measurement in solid tumors

2002 • 48 citations

Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy.

2001 • 46 citations

Proliferation of human colon cancer cells: Role of epidermal growth factor and transforming growth factorα

1992 • 42 citations

Clinical activity of GW572016 in EGF10003 in patients with solid tumors

2004 • 41 citations

Therapeutic opportunities from tumour biology in metastatic colon cancer

2000 • 40 citations

Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)

2004 • 37 citations

Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma.

1998 • 31 citations

The effects of intracolonic EGF on mucosal growth and experimental carcinogenesis

1991 • 31 citations

Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC)

2004 • 29 citations

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (‘Iressa’), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in advanced colorectal cancer (ACRC)

2001 • 28 citations

A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC)

2004 • 25 citations

Constitutive Activation of the Neuregulin-1/erbB Signaling Pathway Promotes the Proliferation of a Human Peripheral Neuroepithelioma Cell Line

2004 • 24 citations

Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors

2004 • 22 citations

A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients

2004 • 21 citations

Expression of epidermal growth factor receptor in normal colonic mucosa and in adenocarcinomas of the colon.

1997 • 20 citations

Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)

2004 • 15 citations

Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study

2004 • 14 citations

The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma

2002 • 13 citations

Progress in Colorectal Cancer Chemotherapy

2000 • 11 citations

Association of Cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225)

2004 • 10 citations

Complications of Malignancy

2004 • 10 citations

A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009)

2004 • 9 citations

Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors

2004 • 7 citations

Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors

2004 • 4 citations

Highlights From: American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium; San Francisco, California January 2004

2004 • 2 citations

Deleted Work

1955 • 0 citations